+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Oncology/Cancer Drugs Market by Drug Class Type and Indication: Global Opportunity Analysis and Industry Forecast, 2018 - 2025

  • ID: 4828906
  • Report
  • February 2019
  • Region: Global
  • 252 pages
  • Allied Analytics LLP
1 of 4
Oncology Drugs Market Overview:

The global oncology/cancer drugs market was valued at $97,401 million in 2017, and is estimated to reach at $176,509 million by 2025, registering a CAGR of 7.6% from 2018 to 2025.

Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option to treat various cancer types, especially blood cancer (leukemia). Rise in incidence of various cancer conditions, increase in popularity of advance therapies (biological and targeted drug therapies), and surge in geriatric population worldwide are the key factors driving the growth of the global oncology/cancer drugs market. Furthermore, rise in cancer awareness and availability of cancer drugs are expected to boost the market growth.

However, high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and increase in number of pipeline products are expected to provide new opportunities for market players in future.

The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers.

Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Key Benefits for Oncology Drugs Market:

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

Oncology Drugs Key Market Segments:

By Drug Class Type

Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy

By Indication

Lung Cancer
Stomach Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Esophagus Cancer
Cervical Cancer
Kidney Cancer
Bladder Cancer
Other Cancers

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
India
China
Japan
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA

List of Key Players Profiled in the Report

AbbVie Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Bristol-Myers Squibb Company
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Johnson & Johnson (Janssen Global Services, LLC,)
Merck & Co., Inc.
Novartis AG
Pfizer Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

Sanofi
Amgen Inc.
Bayer AG
Exelixis, Inc.
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2017
3.3. Top player positioning, 2017
3.4. Porters five forces analysis
3.5. Clinical trials
3.6. Patent analysis (2015-2018)
3.6.1. Patent analysis, world
3.6.2. Patent analysis, by year
3.7. Market dynamics
3.7.1. Drivers
3.7.1.1. Rise in incidence of cancer across the globe
3.7.1.2. Surge in global geriatric population
3.7.1.3. Increase in government expenditures on healthcare
3.7.2. Restraints
3.7.2.1. Adverse effects associated with the use of cancer drugs
3.7.3. Opportunities
3.7.3.1. Untapped emerging economies
3.7.3.2. Increase in number of pipeline drugs
3.7.4. Impact Analyses

CHAPTER 4: ONCOLOGY/ CANCER DRUGS MARKET, BY DRUG CLASS TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Chemotherapy
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Targeted Therapy
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Immunotherapy (Biologic Therapy)
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Hormonal Therapy
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

CHAPTER 5: ONCOLOGY/ CANCER DRUGS MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Lung Cancer
5.2.1. Market size and forecast, by region
5.2.2. Market share analysis, by country
5.3. Stomach Cancer
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Colorectal Cancer
5.4.1. Market size and forecast, by region
5.4.2. Market share analysis, by country
5.5. Breast Cancer
5.5.1. Market size and forecast, by region
5.5.2. Market share analysis, by country
5.6. Prostate Cancer
5.6.1. Market size and forecast, by region
5.6.2. Market share analysis, by country
5.7. Liver Cancer
5.7.1. Market size and forecast, by region
5.7.2. Market share analysis, by country
5.8. Esophagus Cancer
5.8.1. Market size and forecast, by region
5.8.2. Market share analysis, by country
5.9. Cervical Cancer
5.9.1. Market size and forecast, by region
5.9.2. Market share analysis, by country
5.10. Kidney Cancer
5.10.1. Market size and forecast, by region
5.10.2. Market share analysis, by country
5.11. Bladder Cancer
5.11.1. Market size and forecast, by region
5.11.2. Market share analysis, by country
5.12. Other Cancers
5.12.1. Market size and forecast, by region
5.12.2. Market share analysis, by country

CHAPTER 6: ONCOLOGY/ CANCER DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. oncology/cancer drugs market, by drug class type
6.2.2.1.2. U.S. oncology/cancer drugs market, by indication
6.2.2.2. Canada
6.2.2.2.1. Canada oncology/cancer drugs market, by drug class type
6.2.2.2.2. Canada oncology/cancer drugs market, by indication
6.2.2.3. Mexico
6.2.2.3.1. Mexico oncology/cancer drugs market, by drug class type
6.2.2.3.2. Mexico oncology/cancer drugs market, by indication
6.2.3. Market size and forecast, by drug class type
6.2.4. Market size and forecast, by indication
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany oncology/cancer drugs market, by drug class type
6.3.2.1.2. Germany oncology/cancer drugs market, by indication
6.3.2.2. France
6.3.2.2.1. France oncology/cancer drugs market, by drug class type
6.3.2.2.2. France oncology/cancer drugs market, by indication
6.3.2.3. UK
6.3.2.3.1. UK oncology/cancer drugs market, by drug class type
6.3.2.3.2. UK oncology/cancer drugs market, by indication
6.3.2.4. Italy
6.3.2.4.1. Italy oncology/cancer drugs market, by drug class type
6.3.2.4.2. Italy oncology/cancer drugs market, by indication
6.3.2.5. Spain
6.3.2.5.1. Spain oncology/cancer drugs market, by drug class type
6.3.2.5.2. Spain oncology/cancer drugs market, by indication
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe oncology/cancer drugs market, by drug class type
6.3.2.6.2. Rest of Europe oncology/cancer drugs market, by indication
6.3.3. Market size and forecast, by drug class type
6.3.4. Market size and forecast, by indication
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan oncology/cancer drugs market, by drug class type
6.4.2.1.2. Japan oncology/cancer drugs market, by indication
6.4.2.2. China
6.4.2.2.1. China oncology/cancer drugs market, by drug class type
6.4.2.2.2. China oncology/cancer drugs market, by indication
6.4.2.3. Australia
6.4.2.3.1. Australia oncology/cancer drugs market, by drug class type
6.4.2.3.2. Australia oncology/cancer drugs market, by indication
6.4.2.4. India
6.4.2.4.1. India oncology/cancer drugs market, by drug class type
6.4.2.4.2. India oncology/cancer drugs market, by indication
6.4.2.5. South Korea
6.4.2.5.1. South Korea oncology/cancer drugs market, by drug class type
6.4.2.5.2. South Korea oncology/cancer drugs market, by indication
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific oncology/cancer drugs market, by drug class type
6.4.2.6.2. Rest of Asia-Pacific oncology/cancer drugs market, by indication
6.4.3. Market size and forecast, by drug class type
6.4.4. Market size and forecast, by indication
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil oncology/cancer drugs market, by drug class type
6.5.2.1.2. Brazil oncology/cancer drugs market, by indication
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia oncology/cancer drugs market, by drug class type
6.5.2.2.2. Saudi Arabia oncology/cancer drugs market, by indication
6.5.2.3. South Africa
6.5.2.3.1. South Africa oncology/cancer drugs market, by drug class type
6.5.2.3.2. South Africa oncology/cancer drugs market, by indication
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA oncology/cancer drugs market, by drug class type
6.5.2.4.2. Rest of LAMEA oncology/cancer drugs market, by indication
6.5.3. Market size and forecast, by drug class type
6.5.4. Market size and forecast, by indication

CHAPTER 7: COMPANY PROFILES
7.1. AbbVie Inc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. Astellas Pharma Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product Portfolio
7.2.5. Business performance
7.3. AstraZeneca PLC
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product Portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. Bristol-Myers Squibb Company
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product Portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. Celgene Corporation
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product type Portfolio
7.5.5. Business performance
7.6. F. HOFFMANN-LA ROCHE LTD.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. JOHNSON & JOHNSON (Janssen Global Services, LLC,)
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product Portfolio
7.7.5. Business performance
7.8. Merck & Co., Inc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Novartis AG
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance
7.10. Pfizer Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance

*Full List of Tables and Figures Available on Enquiry.

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to this report titled 'Oncology/Cancer drugs market by Treatment Type: Global Opportunity Analysis and Industry Forecast, 2018 - 2025' the market was valued at $97,401 million in 2017, and is projected to reach $176,509 million by 2025, growing at a CAGR of 7.6% from 2018 to 2025.

Cancer is caused when the cells present in the body grow at an uncontrolled rate leading to the formation of a tumor. Cancer has different stages based on its progression. Metastasis is the final stage of the disease, which is marked by the invasion of tumor into others parts of body. The management of cancer in patients requires the use of different drugs such as hormonal therapy, immunotherapy, targeted therapy, and others.

The key drivers of the global oncology/cancer drugs market are surge in geriatric population and rise in collaborations & partnerships to facilitate drug development. In addition, surge in prevalence of cancer and increase in healthcare expenditure have significantly contributed toward the growth of this market. Increase in number of pipeline drugs along with high potential of emerging economies are further expected to provide lucrative opportunities for market expansion. However, adverse effects related to cancer drugs impede the market growth.

The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. Based on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers.

Regionally, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Key Findings of the Oncology/Cancer drugs market:
North America occupied nearly half share of the global oncology/cancer drugs market in 2017.
The immunotherapy segment is anticipated to grow with the highest CAGR throughout the forecast period.
The breast cancer segment accounted for less than one-seventh share of the market in 2017.
Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.
North America was the leading revenue contributor to the global market in 2017, garnering nearly 47.65% of the total market share, owing to high adoption rate of cancer drugs. However, Asia-Pacific is expected to grow at the highest CAGR of 9.5% from 2018 to 2025, owing to increase in disposable income; surge in research, development, & innovation activities; and rise in awareness related to different cancers.
The report provides an extensive competitive analysis and profiles of the key market players such as Amgen Inc., Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi.
Note: Product cover images may vary from those shown
5 of 4

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll